Follow us on




Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Prototype devices

It is recognized that a manufacturer may wish to submit a small number  of "prototype models" of a device to clinical investigation in order to assess safety and/or performance; and those such prototypes may need to undergo a number of changes prior to large-scale production.

 Forums
Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :NIPER to organize 5-day workshop on 'Clinical Trial Protocol Writing' .. 2009-08-24 18:37:32 
ramakrishna
Newbie
Joined: 2009-07-24 15:13:12
Posts: 10
Location
Subject :NIPER to organize 5-day workshop on 'Clinical Trial Protocol Writing' from Aug 24

 
 

The National Institute of Pharmaceutical Education and Research (NIPER), Chandigarh, in association with Department of Pharmaceuticals, is organizing a five-day workshop on 'Clinical Trial Protocol Writing' from August 24 to 28, 2009.

The workshop is significant because a well-written clinical trial protocol allows researchers at multiple locations to perform the study in exactly the same way, so that their data can be integrated as though they were all working together.

The five-day workshop will have a comprehensive coverage on clinical trial protocol writing. Topics like basics of medical writing; writing SOPs; understanding of research designs; designing a study protocol; clinical trial protocol writing and clinical research report writing will be covered in the workshop by experts.

A clinical trial protocol is a document that describes the objective(s), design, methodology, statistical considerations, and organization of a clinical trial. The protocol usually also gives the background and reason the trial is being conducted, but these could be provided in other background and reason the trial is being conducted, but these could be provided in other documents.

The protocol contains a study plan on which the clinical trial is based. This plan is designed to safeguard the health of the participants (while limiting their financial liability) as well as answer specific research questions. The protocol describes, among other things, what types of people may participate in the trial; the schedule of tests, procedures, medications and dosages; and the length of the study.

The focus area of the workshop is to provide advancement in knowledge and skills of persons working or intending to work in clinical research. This workshop will be of special use to professionals and students associated with pharmaceutical and biotechnology industry, academic institutions, regulatory agencies, clinical research organizations and healthcare Industry.

The coordinator of the workshop, professor Pramil Tiwari said that the workshop will be of interest to the CRAs and investigators working in the field who are looking for the additional training; professionals wanting to change career within the industry/ academia to clinical research; professionals willing to get in the field of clinical research and to recently employed personnel in academia or industry requiring comprehensive training in clinical research.

Prominent personalities and experts, drawn from industry, regulatory bodies and the academia, who will deliver lectures in the workshop include Dr Vasantha Muthuswamy, former senior DDG, ICMR, New Delhi; Dr B Chakraborti, vice president, Cadila, Ahmedabad; Dr Rajesh Kher, GVK-Bio; Pralhad Dhagale, Novartis, Hyderabad; Dr R M Pandey, AIIMS, New Delhi; Dr C K Katiyar, Dabur and Dr Roma Uppal, ex- professor, PGIMER, Chandigarh.

IP Logged
Page # 


Powered by ccBoard